As­traZeneca spins out 6 drugs and an R&D group in­to Viela Bio, which emerges with a piv­otal pro­gram and $250M

8 years ago
Financing

Cel­gene shak­en again af­ter the FDA kicks back their mar­ket­ing ap­pli­ca­tion on block­buster hope­ful ozan­i­mod

8 years ago
R&D

Ex­elix­is/Dai­ichi Sankyo ask Japan­ese reg­u­la­tors for green light on hy­per­ten­sion drug; Bris­tol-My­ers Squibb li­cens­es ...

8 years ago
News Briefing

No­var­tis’ on­col­o­gy re­search chief in Chi­na jumps to up­start EpimAb in Shang­hai

8 years ago
People
China

J&J col­lab­o­rates with Aldeyra on new drugs for sys­temic in­flam­ma­to­ry dis­eases

8 years ago
R&D
Pharma

Dana-Far­ber’s Lau­rie Glim­ch­er helps launch a NYC biotech up­start with some key in­sights on im­muno-on­col­o­gy tech

8 years ago
Financing
Startups

Haul­ing in a $100M mega-round, gene ther­a­py start­up Gen­er­a­tion Bio builds al­ter­na­tive to po­ten­tial­ly risky vi­ral ...

8 years ago
Financing
Startups

Com­put­er sci­ence and en­gi­neer­ing, meet drug R&D. MIT star Tim­o­thy Lu in­ter­twines tech­nolo­gies for an off­beat biotech ...

8 years ago
Financing
Startups

Glob­al syn­di­cate backs Prokar­i­um's $10M round; Bavar­i­an Nordic to test can­cer vac­cine with Imfinzi; AI start­up buys ...

8 years ago
News Briefing

Ver­tex CMO Jef­frey Chodake­witz is hit­ting the ex­it doors. What's next?

8 years ago
People

Stock nose­dives for car­dio­vas­cu­lar drug­mak­er Ar­ca fol­low­ing Phase IIb AF fail­ure

8 years ago
R&D

Sov­er­eign non­sense: Patent board joins the line­up of crit­ics diss­ing Al­ler­gan's 'il­lu­so­ry' IP deal with the Mo­hawks

8 years ago
Pharma

Ob­sE­va high­lights a pos­i­tive da­ta point from its PhI­II study of new fer­til­i­ty drug, beats a path to reg­u­la­tors

8 years ago
R&D

Johns Hop­kins spin­out spot­lights a show­case an­i­mal test for an­ti­body-lig­and I/O traps — match­ing check­points with a ...

8 years ago
AI

Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017

8 years ago
Discovery
In Focus

FDA pro­vides a long-de­layed OK for Kem­Pharm’s opi­oid — with strings at­tached

8 years ago
Pharma

Up­start GeneTx launch­es, go­ing head to head with Ovid on rare An­gel­man syn­drome

8 years ago
Startups

Seek­ing greater gen­der di­ver­si­ty, Al­ny­lam pro­motes four fe­male lead­ers; Paul Hast­ings starts post-On­coMed ca­reer as ...

8 years ago
Peer Review

Mer­ck­'s melanoma drug shows ear­ly promise for re­sis­tant can­cers in PhI tri­al

8 years ago
R&D

FDA of­fers quick re­view for Shire's prospec­tive block­buster lanadelum­ab; Big Phar­ma loves big buy­backs

8 years ago
News Briefing

The Trump ef­fect: PwC re­port says the FDA has slammed the brakes on sig­nif­i­cant new drug reg­u­la­tions

8 years ago
R&D
Pharma

Hit by an ex­pect­ed EMA re­jec­tion, Puma plans to ap­peal neg­a­tive opin­ion on ner­a­tinib

8 years ago
Pharma

Sh­iono­gi, Roche get their first ap­proval for the next big thing in fight­ing the flu

8 years ago
Pharma

Bel­licum out­lines a few quick steps the FDA wants be­fore lift­ing its hold on lead cell ther­a­py, shares rise

8 years ago
Cell/Gene Tx
First page Previous page 1050105110521053105410551056 Next page Last page
A service from the Financial Times